Joshua Burns

Congratulations to GRIN Advisory Board member, Professor Joshua Burns

by | Oct 19, 2023 | 0 comments

Congratulations to GRIN Advisory Board member, Professor Joshua Burns, for being recognized by the Australian Academy of Health and Medical Sciences for his outstanding contributions to medical and health sciences.

“Fellows are elected by their peers for their significant contributions to health and medical sciences – it is a selective process that recognizes the best and brightest in Australia and highlights those who are truly making a difference in health,” said the Academy’s Interim President Professor Ingrid Scheffer AO FRS FAA FAHMS.

Professor Burns is the inventor of, a web-based scoring system for monitoring response to therapy, housing key clinical trial endpoints such as the Charcot-Marie-Tooth Pediatric Scale (CMTPedS), CMT Functional Outcome Measure (CMT-FOM), CMT Infant Scale (CMTInfS), Rasch-modified CMT Neuropathy Score (CMTNSv2-R) and items from the 1000 Norms Project. This work is critical to the preparation for clinical trials for the treatment of the CMT.

HNF recently launched its CMT Pediatric Natural History Study project in which clinical evaluation data will be collected in the Global Registry for Inherited Neuropathies (GRIN), in addition to the patient-reported data and genetic reports. In August, an associate of Dr. Burns, Dr. Kayla Cornett, PhD, trained and certified the Physical Therapy and Occupational Therapy staff at both Lurie’s Children’s Hospital and Arkansas Children’s Hospital. The certification is required to conduct the CMT Pediatric Scale and the CMT Infant Scale, both of which are a part of the clinical evaluation for our CMT Pediatric Natural History project. This study is currently in progress.

If you would like to inquire about participation in this study, please contact [email protected].

Learn more on this topic

Related Blog Posts

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

New Study on CMT Type 2B

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Allison Moore is going to be published!

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

HNF-WVU-NIOSH Study update:

We are pleased to update our readers on the progress of the WVU-NIOSH study, “A Bi-Directional Translational Model of Exercise Training in the Treatment of Charcot-Marie-Tooth Disease”

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news